---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-014759"
form_type: "8-K"
ticker: "PFE"
cik: "0000078003"
company_name: "PFIZER INC"
filed_at: "2023-05-02T23:59:59+00:00"
generated_at: "2026-06-16T04:13:52.145185+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pfizer Q1 revenue falls 29% to $18.3B; adjusted EPS $1.23; reaffirms FY2023 guidance

## Summary
- First-quarter 2023 revenues $18.3B (down 29% YoY); reported diluted EPS $0.97, adjusted diluted EPS $1.23 (down 24% YoY).
- Comirnaty revenues dropped 75% operationally; Paxlovid revenues increased by $2.8B; ex-COVID products grew 5% operationally.
- FY2023 guidance reaffirmed: revenue $67-71B, adjusted EPS $3.25-3.45; midpoint implies ~31% operational revenue decline.
- Proposed acquisition of Seagen (oncology ADC) expected to close late 2023 or early 2024; integration planning underway.

## SEC filing metadata
- accession: 0001628280-23-014759
- form_type: 8-K
- ticker: PFE
- cik: 0000078003
- company_name: PFIZER INC
- filed_at: 2023-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/78003/000162828023014759/0001628280-23-014759-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/78003/000162828023014759/pfe-20230502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-014759
- JSON: https://secwatch.observer/filing/0001628280-23-014759.json
- Plain text: https://secwatch.observer/filing/0001628280-23-014759.txt

## Key facts
- Earnings Releases
  PFIZER INC reported first quarter of 2023 results: revenue $18,282 million, net income $5,543 million, EPS $0.97 per diluted share. Guidance reaffirmed.
  - Period: first quarter of 2023
  - Revenue: $18,282 million
  - Net income: $5,543 million
  - EPS: $0.97 per diluted share
  - Guidance: reaffirmed
  - Result: reported results
  source text: except as shall be expressly set forth by specific reference in such filing. --- EX-99 (EX-99) --- Pfizer Reports First-Quarter 2023 Results ▪ First-Quarter 2023 Revenues of $18.3 Billion – Expected Decline in Comirnaty (1) Revenue Drove 26% Operational Decrease in First-Quarter 2023 Revenues – First-Quarter 2023 Revenues from Comirnaty (1) and Paxlovid of $7.1
  evidence_url: https://www.sec.gov/Archives/edgar/data/78003/000162828023014759/0001628280-23-014759-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.